Lumpectomy vs Mastectomy: Which Is Right for You?

Lumpectomy vs Mastectomy: When you are diagnosed with breast cancer, it is like a kick in the stomach. It is natural to be scared, overwhelmed or confused by everything that comes at you. It is important for you to remember that you are not the only one: breast cancer is highly prevalent (1 in 8 women in the U.S will be diagnosed with the disease in her lifetime), and thousands of breast cancer survivors have just walked this path before you. An example is, you might be having doubts about surgery options such as lumpetomy vs mastectomy and which one will most likely be the best option to you. There is nothing wrong with having questions and also having time to be ready this guide will explain some of the things that are involved in each surgery and how they are different.

In this post, we’ll cover:

  • The differences between lumpetomy and mastectomy (which one is included in each operation).
  • Advantages and disadvantages of each choice and their implication on appearance and life.
  • Survival and recurrence: the research indicates that lumpectomy (with radiation) and mastectomy are same in terms of their long-term results.
  • Healing and side effects: the possible difference in healing and lifestyle based on the type of surgery performed.
  • Things to consider: personal and medical reasons that will assist you in making the decision that is right to you.

We want to provide you with clear and understanding information, which is compassionate in order to make you feel supported and informed. At the conclusion of this article, you will be in a better position to understand both lumpectomy and mastectomy; their differences, their advantages and disadvantages as well as expectations so that you can make the right decision that suits you and your future.

Difference Between lumpectomy vs mastectomy

  • Tissue removed: Lumpectomy excises just the tumor and a small margin of normal breast, so most of the breast remains. Mastectomy removes the entire breast, often including the nipple and areola. (Some mastectomies spare the skin or nipple to aid reconstruction.)
  • Hospital stay: Lumpectomy is usually an outpatient procedure, most women go home the same day. Mastectomy is more extensive and generally requires at least one overnight hospital stay.
  • Radiation therapy: Lumpectomy always requires follow-up radiation (typically daily sessions for ~5–7 weeks) to kill any remaining cancer cells. Mastectomy may let you skip radiation – many mastectomy patients (especially with small, early tumors) do not need radiation afterwards. If a lumpectomy patient cannot receive radiation (due to distance or health reasons), a mastectomy is usually preferred.
  • Recovery and impact: Lumpectomy is less invasive and leaves the breast mostly intact. You’ll have a scar at the tumor site, but the overall breast shape is preserved. Mastectomy removes the whole breast, which dramatically alters chest appearance. (Women often choose breast reconstruction with implants or tissue flaps to rebuild the breast mound after mastectomy.

Lumpectomy vs Mastectomy: Survival Rate

Multiple studies show long-term survival is essentially the same whether you have lumpectomy (plus radiation) or mastectomy for early-stage cancer. In fact, Dr. Tari King (chief of breast surgery at Dana-Farber Brigham Cancer Center) emphasizes that “breast cancer recurrence is not impacted by the type of surgery. It’s the whole treatment package that matters”. Large trials have confirmed this: for example, a 20-year follow-up found no significant difference in overall survival between breast-conserving therapy and mastectomy. 

In one study, 20-year survival was about 44.5% with mastectomy vs 39.1% with lumpectomy + radiation (a non-significant difference). Likewise, in non-invasive (DCIS) cases, 10-year breast-cancer survival was ~98–99% for lumpectomy + RT vs mastectomy.

  • Local recurrence: Lumpectomy + RT has a slightly higher risk of cancer coming back in the same breast compared to mastectomy. Huntsman Cancer Center surgeon Dr. Cindy Matsen notes that 10–15 year chest-wall recurrence after mastectomy is only about 1–3%, versus roughly 5–7% after lumpectomy + RT. Even so, both rates are low, and additional treatments (like surgery or radiation) can address local recurrences.
  • Distant (metastatic) recurrence: The chance of cancer spreading elsewhere in the body is the same with either surgery. In other words, mastectomy does not reduce the risk of distant recurrence beyond what lumpectomy with radiation achieves.

Expert insight: Dr. King points out that modern systemic therapies (chemotherapy, hormone/ her2 drugs) have made local recurrence rates “exceedingly low… the risk is very low and is the same whether I remove the breast or conserve it”. In other words, survival and spread depend more on tumor biology and adjuvant treatments than on surgery type.

Lumpectomy vs Mastectomy Recovery

Recovery differs significantly between these surgeries:

  • Hospital stay: Most lumpectomy patients leave the hospital the same day. Mastectomy patients usually stay 1–2 days for monitoring and wound care.
  • Time off work/activities: After a lumpectomy (with sentinel-node biopsy), many women resume normal activities in 5–10 days. After a mastectomy, it typically takes 3–4 weeks (and up to 6–8 weeks if reconstruction was done) before you feel like yourself again.
  • Physical side effects: Both surgeries cause soreness in the chest, arm, and shoulder (especially if lymph nodes are removed). Mastectomy is more invasive and often involves surgical drains, so pain, swelling or fatigue tend to be greater.
  • Radiation: All lumpectomy patients require radiation therapy after surgery. This means daily trips to a treatment center for several weeks. In contrast, many mastectomy patients avoid radiation entirely, though some may still need it depending on tumor size or node involvement. (Discuss with your doctor whether radiation is likely after each option.)
  • Other treatments: Importantly, the choice of surgery does not change whether you need chemotherapy, hormone therapy or targeted drugs. Those decisions are based on the cancer’s stage and biology, not the type of surgery.
  • Advantages and disadvantages of Lumpectomy and Mastectomy

Lumpectomy (Breast-Conserving Surgery)

  • Pros: You retain the majority of your breast, nipple, as well as the chest. The nipple sensation and skin sensation is generally intact and breast-feeding can still be done. It is a quick (usually less than an hour) surgery and a quick recovery- the majority of women discharge on the same day.
  • Cons: Requires a course of radiation therapy, which can have side effects and requires weeks of treatment. The shape of the breast may change (dimples or asymmetry) after tissue removal. Sometimes cancer cells are found at the margin, necessitating a second surgery. Lumpectomy is generally not an option if you cannot have radiation, have multiple tumor sites, or previously had chest radiation. It’s also less suitable for inflammatory breast cancer or for women with high-risk genetic mutations (BRCA1/2, etc.) that greatly increase the chance of new tumors.

Mastectomy

  • Pros: Removes nearly all breast tissue, lowering (to near zero) the chance of a cancer recurrence in the breast. Many women can skip radiation after mastectomy (radiation is only needed if nodes are positive or other risk factors exist). Mastectomy is often recommended if you carry a high-risk gene mutation or have very extensive disease. For some women, having a mastectomy provides peace of mind – knowing all breast tissue is gone. And if you do not plan reconstruction, you usually avoid any future breast surgeries.
  • Cons: Major surgery with a longer, harder recovery. You will lose your breast and nipple, which can impact body image and sensation. (Breast reconstruction is an option, but it means more surgery down the road.) Mastectomy has higher risks of complications like infection or lymphedema (arm swelling). Most patients lose all feeling in the chest skin and nipple after mastectomy, which can affect quality of life.

Figure: A plastic surgeon holds a silicone breast implant, illustrating one option for breast reconstruction after mastectomy. Breast Reconstruction: Many women choose to rebuild the breast shape after mastectomy using implants or tissue flapshealthcare.utah.edu. Reconstruction can improve appearance and body image, but it involves additional surgery and recovery. Note that implants or flap surgeries restore the shape of a breast but cannot recreate natural sensation or milk productionhealthcare.utah.edu.

Other Breast Cancer Surgery Options

Besides standard lumpectomy and mastectomy, there are variations and related procedures:

  • Mastectomy types: In addition to total (simple) mastectomy, surgeons may perform a skin-sparing or nipple-sparing mastectomy, which preserves more of the breast skin or the nipple-areola complex for cosmetic benefit. A modified radical mastectomy removes the breast plus many lymph nodes under the arm (axilla).
  • Contralateral prophylactic mastectomy: Some women at very high risk (e.g. strong family history or BRCA mutation) choose to remove the opposite healthy breast along with the cancerous one. This doubles the mastectomy, but data show it generally does not improve overall survival for average-risk patients. (It may be considered in specific high-risk cases.)
  • Sentinel node biopsy: Nearly all patients will have evaluation of the underarm lymph nodes to check for spread. Doctors usually combine a lumpectomy or mastectomy with a sentinel lymph node biopsy (removing 1–3 nodes). If those nodes are clear, no further surgery is required; if they’re positive, doctors may remove or treat additional nodes. Lymph node removal, even if only sentinel nodes, carries a small risk of arm swelling (lymphedema) for both lumpectomy and mastectomy patients.
  • Neoadjuvant therapy: For larger tumors, doctors sometimes give chemotherapy or hormonal therapy before surgery to shrink the tumor, making a lumpectomy possible instead of a mastectomy.

Ultimately, you and your doctor will decide based on your cancer stage, tumor biology, genetics, medical history, and personal preferences. As Susan G. Komen advises, “If you have a choice, study your options. Weigh the risks and benefits of each surgery and choose the one that’s right for you”

Remember that in most early cases, lumpectomy + radiation and mastectomy offer equivalent survival. Which is “right” depends on factors like tumor size (e.g. lumpectomy usually only for smaller tumors), need for radiation, genetics, and how you balance peace-of-mind versus preserving your body.

Talk with your healthcare team: No blog can replace a personalized medical consultation. Discuss candidly with your surgeon and oncologist. They can explain whether you are a candidate for breast-conserving surgery and help you understand outcomes. As one expert notes, “getting a mastectomy vs lumpectomy with radiation does not reduce the risk [of recurrence], nor does it improve survival… it’s the whole package of treatment that matters”.

Make sure you are comfortable with the plan – and don’t hesitate to get a second opinion if you’re uncertain. You should base your treatment choice on the latest data, your doctor’s guidance, and your own priorities.

Conclusion

For early-stage breast cancer, lumpectomy (with radiation) and mastectomy offer similarly high success rates. Decades of research have shown that women treated with lumpectomy plus radiation have essentially the same long-term survival as those having mastectomy. In other words, neither surgery “wins” on survival – both dramatically reduce the risk of dying from breast cancer by the same amount. 

Each option offers different trade-offs: a lumpectomy preserves most of the breast and usually enables a quicker recovery, while a mastectomy involves more extensive surgery (often requiring an overnight hospital stay) but may give some women extra peace of mind since it removes the entire breast.

Lumpectomy does carry a slightly higher chance of the cancer coming back in the same breast, but any local recurrence is typically treatable and does not change the fact that distant (metastatic) outcomes are the same between the two approaches.

Ultimately, the right choice depends on your unique situation. Your care team will consider many factors – tumor size and location, genetic test results, your health and age, access to follow-up radiation, and most importantly your personal feelings and goals – when advising one option over the other.

Be free to discuss with your surgeons and oncologists: inquire about risks and benefits in your case, and there is nothing wrong with seeking a second opinion. Lumpectomy and mastectomy are both acceptable forms of treatment. By staying informed and working with your breast cancer care team, you can make the right decision.

Call-to-Action

We understand that this is an overwhelming time. At our clinic, we are here to support you every step of the way. Our experienced breast cancer specialists will take the time to explain all of your surgical options and what they mean for you. We invite you to contact us to discuss your diagnosis and treatment goals. 

Whether you need more information about lumpectomy versus mastectomy, have questions about reconstruction, or want a personalized care plan, our team is ready to help. We will hear you, respond to your questions in an empathetic manner, and we will create a treatment plan mounting on your needs. We prioritize your comfort and confidence above all else and are proud to be part of your care team.

FAQs

  • 1. Is lumpectomy safer than mastectomy?
    Both are equally safe with similar survival rates. Lumpectomy keeps most of the breast but has a slightly higher chance of local recurrence.
  • 2. Can I choose mastectomy if lumpectomy is possible?
    Yes. Both options offer the same survival. The choice depends on your comfort, recovery preference, and peace of mind.
  • 3. Do I need radiation after surgery?
    Usually after lumpectomy, yes. After a mastectomy, doctors recommend it only if the cancer spreads to lymph nodes or the tumor is large.

    4. How does each affect emotions?
    Mastectomy may impact body image more, while lumpectomy preserves appearance. Support groups can help recovery.
  • 5. Which surgery has faster recovery?
    Lumpectomy heals in days; mastectomy may take weeks, especially with reconstruction.
Best Lung Cancer Treatment Options in the US_CurePoint Cancer Center

Best Lung Cancer Treatment Options in the U.S. (2025 Guide)

Treatment of Lung Cancer I CurePoint Cancer Center US

The treatment of lung cancer has changed quickly and the emergence of new therapies, guidelines and precision medicine has redefined the possibilities. Whether you or a loved one are considering treatment options of lung cancer, this 2025 guide will decipher the most effective treatment options in the U.S. based on the type of cancer, stage, and new developments. We will also indicate what hospitals, new treatments and new options to anticipate.


Understanding the Basics: What Impacts Treatment Choice

Before diving into specific treatments, keep in mind that the choice of lung cancer treatment depends on:

  • The lung cancer type (primarily), non-small cell lung cancer [NSCLC] vs small cell lung cancer [SCLC])
  • Localization of disease (localized, locally advanced, metastatic)
  • Genetic/Molecular biomarkers (e.g. EGFR, ALK, ROS1, MET, HER2, etc.)
  • General health of patient, comorbidities and patient preferences.

Being aware of these assists in the assessment of what is best in your situation.


Standard Treatment Options in 2025

Here are the core lung cancer treatment options available in the U.S. in 2025:

Treatment ModalityWhen UsedBenefits & Trade-offs
SurgeryIn stage-I and stage-II resectable NSCLC.Potentially curative; less aggressive systemic side effects; is contingent on surgical risk.
Radiation / Stereotactic Body Radiotherapy (SBRT)Early-to-locally advanced, or in cases in which surgery is not possible.Greater accuracy, less sessions; at the cost of surrounding tissue.
ChemotherapyFrequently as complement to surgery, or in metastatic/advanced disease.Widespread; higher amount of side effects; conventional backbone when biomarkers are not present.
Targeted TherapyWith actionable gene mutations (EGFR, ALK, ROS1, MET, HER2, etc.)in NSCLC.The toleration is often better; it may result in a longer progression-free survival. Requires genetic testing.
ImmunotherapyPD-1 / PD-L1 inhibitors, with or without chemotherapy, high PD-L1 activity.Lasting effects in some patients; there is the risk of immune-related adverse effects.
Combination TherapiesIntegration of immunotherapy, chemo, targeted agents or newer agents.Ability to enhance performance; more complicated side effects and price.

What’s New & Advanced in Lung Cancer Treatment

The most appropriate lung cancer treatment plans to rely on in 2025 do not necessarily include the most common ones, there are the new lung cancer therapy and other forms of lung cancer treatment that are making a difference. The most promising of them are:

  1. ROS1-Positive NSCLC Treatment:
    • Taletrectinib (Ibtrozi) was approved by the FDA on June 11, 2025. Efficacy based on the TRUST-I and TRUST-II trials, both in ROS1 TKI-naïve and previously ROS1 TKI-treated patients.
    • It is an oral targeted therapy, which enhances the response rates with this infrequent subtype.
  2. Novel Approved Drugs for Specific Mutations:
    • Zenocutuzumab-zbco (Bizengri) is currently used for NSCLC or pancreatic adenocarcinoma with NRG1 gene fusion, following prior systemic therapy.
    • In December 2024 Ensartinib (Ensacove) was approved by the FDA on December 18, 2024. Comes from the phase 3 eXalt3 trial, which showed improved progression-free survival compared to crizotinib.
  3. Antibody-Drug Conjugates & Combination Therapies:
    • There are some new therapies which include a combination of targeted agents, the new delivery system or immunotherapy. Indicatively, AACR 2025 progresses such as EGFR, ROS1, and other target resistance overcome drugs.
  4. Guidelines Updates:
    • The NCCN Guidelines are also updated to showcase new first-line agents, particularly in patients who do not have a driver change.
    • The CHEST guideline, which is expected to be published mid 2025, provides evidence-based advice on how to treat early-stage NSCLC to facilitate the decision of whether to consider surgery or SBRT as well as adjuvant therapies.

Best Hospitals & Centers for Lung Cancer in the U.S.

Choosing a top hospital can significantly affect outcomes. “Best hospital for lung cancer” really means one with:

  • Multidisciplinary cancer care teams (thoracic surgery, medical oncology, radiation oncology)
  • Access to the latest advanced lung cancer treatment options and clinical trials
  • High surgical and treatment volume, which often correlates with better results
  • Strong supportive care (managing side effects, rehabilitation)

Some institutions frequently cited among top U.S. lung cancer centers:

  • CurePoint Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Dana-Farber Cancer Institute
  • Mayo Clinic
  • MD Anderson Cancer Center
  • University of Texas, MD Anderson
  • Stanford Cancer Center

Each of these is known to adopt the newest guidelines and therapies quickly, including precision medicine, immunotherapy, and access to experimental treatments.


How to Choose Among Treatment Options

The following are measures to assist in making the appropriate decision when it comes to treatment of lung cancer:

  1. Full molecular profiling: In case of biopsy, EGFR, ALK, ROS1, MET, HER2, etc. These will determine whether you can receive specific treatment or state-of-the-art treatments.
  2. Take into account stage and resectability: Aggressive disease at an early stage can be treated using surgery; progressive disease requires systemic therapy.
  3. Check immunotherapy eligibility: PD-L1 or other biomarker expression can be used to determine the possibility of immunotherapy being effective.
  4. Consider benefits and drawbacks: The issue of side effects, price, comfort, and quality of life. New treatments can be less side-effected or better tolerated, but also more expensive or more monitored.
  5. Look into clinical trials: For many patients, especially with rarer mutations or resistance to standard treatment, participation in trials gives access to new lung cancer therapies ahead of broad availability.

What’s on the Horizon & Evolving

The following are some of the trends that can be taken into consideration in the future:

  • Above mentioned novel drug approvals in infrequent fusions or gene mutants.
  • There are other antibody-drug conjugates (ADCs) which contain special markers.
  • Improved combinations of immunotherapy and resistance of the immunity strategies to overcome.
  • Better understanding of microenvironment of tumor, circulating tumor DNA (liquid biopsies) to treat and monitor and personalized medicine.
  • Supplementary care and treatment planning to minimize the side effects and maximise efficacy.

Conclusion

The optimal way to treat lung cancer in your case depends on numerous factors: type of cancer and its stage, genetic markers, health condition, and your preferences. By 2025, the U.S. has a broad selection of robust treatment options, such as surgery and radiation, or the latest treatment options to treat lung cancer, such as targeted drugs, immunotherapies, and new drugs.

When you are talking to your oncologist about your plan, be sure to ask:

  • Do I possess actionable biomarkers or mutations which these sophisticated therapies are directed at?
  • Is my condition in stage one in which surgery or SBRT can be performed?
  • What are the clinical trials that I may qualify for?
  • What are the results of these new therapies in my local hospitals and which ones have those treatments?

Keeping up to date can enable you to make the most effective decisions by taking into account the side effects, quality of life and cost of the decision made.

Call-to-Action (CTA)

At CurePoint Cancer, we are here to help patients find the most optimal treatment options available for lung cancer in the U.S. today and talk to our specialists to find their own treatment plans and support services.

Call us today to receive professional advice on lung cancer.

FAQs

Q1. Which is the best U.S. lung cancer hospital?

A: CurePoint Cancer Center, MD Anderson, Mayo Clinic, Memorial Sloan Kettering, Cleveland Clinic, and Dana-Farber are believed to be the best hospitals.

Q2. Is immunotherapy effective against lung cancer?

A: Yes, immunotherapy proved to be extraordinarily useful in enhancing the survival of non-small cell lung cancer of advanced types.

Q3. Can new lung cancer therapies replace chemotherapy?

A: Despite the existence of patients more responsive to immunotherapy or targeted drugs, chemotherapy is broad and tends to be employed in combination with new therapies.

Q4. So where am I going to get these support groups for lung cancer patients?

A: There are community and support groups in LUNGevity Foundation and American Cancer Society across the nation.

Q5. What are the newest lung cancer treatment options in the U.S.?

A: The latest options include immunotherapy, targeted therapy, proton therapy, and CAR-T cell therapy (in trials).

The-Bobby-Dodd-Institute

Phillip E. Miles: Transforming Georgia’s Healthcare Landscape with Vision and Compassion

Introduction: A Legacy Rooted in Purpose

For more than 20 years, Phillip E. Miles has been a standout figure in Georgia’s ever-evolving healthcare landscape. Miles, a native of Atlanta, and a graduate of the renowned Georgia Institute of Technology has become a household name when it comes to bringing change to a community, particularly underserved and lacked-upon areas. 

His experience as an entrepreneur and the modern-day healthcare advisor and provider shows a story of leadership, innovation, and staying strong in the face of adversity.

Corporate Excellence to Healthcare Visionary

Phillip E. Miles began his professional journey in the financial sector at Arthur Andersen, where he rose to the position of Southeast Tax Partner, specializing in mergers and acquisitions.

These were his early-childhood experiences that made him have a nexus of eye towards strategic development and operational excellence- which he would later apply in the healthcare arena.

The-Bobby-Dodd-Institute

Dedication to Social Impact: The Bobby Dodd Institute

Miles is a true believer of social good. He served as a board member (and eventually Chairman) of the Bobby Dodd Institute which led efforts to offer jobs to disabled people.In recognition of his outstanding contributions, he was honored with the Circle of Excellence Award in 2014. This experience reconfirmed his faith that healthcare and social responsibility needs to complement one another.

Leading the Charge in Community Healthcare

  • Over the past 15 years, Phillip E. Miles has transitioned into a direct role in healthcare leadership. In his work there is:
  • Management of cancer and urology practices in the state of Georgia
  • Streamlining of care delivery through managing laboratories and revenue cycle systems
  • The increase of Federally Qualified Health Clinics (FQHCs) in order to expand the access

These roles have enabled Miles to establish holistic care settings that do not only take care of ill people but also wellness, dignity and access among the marginalized groups.

Revolutionizing Technology in Healthcare

One of Miles’s most innovative projects is the development of MyHealthAI.org, a first-of-its-kind HIPAA-compliant medical app. This platform empowers patients with features like:

  • Secure medical record storage
  • Remote patient monitoring tools
  • Direct communication channels with providers

By integrating AI and mobile technology, this app represents a crucial step in bridging the gap between patients and providers — especially in rural and underserved areas.

Personal Strength: A Cancer Survivor's Mission

Perhaps what sets Miles apart the most is his personal battle with leukemia. He’s not just a healthcare leader—he’s lived the cancer journey, surviving a bone marrow transplant and emerging with deep empathy and strength. This experience has strengthened his resolve to:

  • Improve cancer care infrastructure.
  • Expand services like hematology and oncology to new clinics.
  • Ensure affordability and compassion in care delivery.

His survival story adds depth to his mission and authenticity to his advocacy.

CurePoint Cancer Treatment Centers: A Beacon of Hope

Under Phillip E. Miles’ leadership, CurePoint Cancer Treatment Centers have become a benchmark for blending advanced care with personal touch. These centers provide specialized treatments in oncology, radiology, and diagnostics — while staying deeply committed to serving underserved communities across Georgia.

Key pillars of CurePoint’s model under Miles’s guidance include:

  • Advanced cancer diagnostics
  • Patient-first, community-centric care
  • Partnerships with public and private health entities

Explore more at CurePoint Cancer

Building a Collaborative Future

Phillip E. Miles’s partnerships extend beyond CurePoint. Through his roles at Central GA Urology and Lab Services of GA, he promotes:

  • Technological innovation in urology care.
  • Personalized diagnostics.
  • Integrated service delivery models.

He aims to develop integrated healthcare systems where every individual has access to quality, timely care.

Conclusion: Leadership That Truly Serves

With rising healthcare challenges and ongoing disparities, Phillip E. Miles offers more than ideas—he delivers measurable impact. With a rare combination of business sense, healthcare insight, and genuine compassion, Miles is shaping a more equitable and innovative future for Georgia.

Whether it’s launching a revolutionary app, supporting FQHCs, or managing top-tier cancer centers, his focus remains on one thing — the patient.

Internal Links for SEO:

Frequently Asked Questions (FAQs)

A: Phillip E. Miles is a Georgia-based healthcare executive, cancer survivor, and medical advisor known for his work with cancer clinics, Federally Qualified Health Centers, and innovative digital health solutions.

 A: MyHealthAI.org is a HIPAA-compliant app co-developed by Miles that offers secure medical record storage, remote monitoring, and direct communication between patients and doctors.

A: Under Phillip E. Miles’s leadership, CurePoint provides advanced, affordable cancer care across Georgia with a focus on accessibility, diagnostics, and compassionate patient experiences.

A: He served as Chairman of the Bobby Dodd Institute, a nationally recognized nonprofit for people with disabilities, and received the Circle of Excellence Award for his efforts.

A: As a leukemia bone marrow survivor, Miles brings deep empathy and firsthand experience to his mission of improving healthcare access, especially for underserved populations.